Role of C-Reactive Protein When Prescribing a Statin

被引:0
作者
Scott Kinlay
机构
[1] Brigham and Women’s Hospital,VA Boston Healthcare System
[2] and Harvard Medical School,Cardiovascular Division
[3] VA Boston Healthcare System,undefined
来源
Current Atherosclerosis Reports | 2012年 / 14卷
关键词
C-reactive protein; CRP; LDL cholesterol; Screening; High-risk strategy; Variability; Prediction;
D O I
暂无
中图分类号
学科分类号
摘要
The clinical value of measuring C-reactive protein (CRP) to guide statin therapy is uncertain. It has no value in patients at high risk who would be treated regardless of CRP (eg, patients with coronary disease or of equivalent risk), in patients at low risk who do not warrant treatment, and those with other acute or chronic inflammatory conditions that amplify CRP. Drawbacks to the widespread clinical use of CRP include its small impact on risk prediction beyond other risk factors, and evidence from JUPITER and other trials that baseline CRP is unable to identify patients who obtain greater absolute benefits from statin therapy. Furthermore, the within-person variability of CRP is about the same as the reduction in CRP from intensive statin therapy, and this leads to many patients registering an increase in CRP with treatment. For these reasons, CRP has no clear role in determining who should receive statin therapy or for monitoring the success of treatment.
引用
收藏
页码:26 / 32
页数:6
相关论文
共 171 条
[1]  
Grundy SM(2002)Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 3143-421
[2]  
Cleeman JI(2004)Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation. 110 227-239
[3]  
Merz CN(2006)AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation. 113 2363-2372
[4]  
Brewer HB(1985)Sick individuals and sick populations Int J Epidemiol. 14 32-38
[5]  
Clark LT(2009)Life-years gained among US adults from modern treatments and changes in the prevalence of 6 coronary heart disease risk factors between 1980 and 2000 Am J Epidemiol. 170 229-236
[6]  
Hunninghake DB(2000)Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations Lancet. 355 675-687
[7]  
Smith SC(1999)Acute-phase proteins and other systemic responses to inflammation N Engl J Med. 340 448-454
[8]  
Allen J(1990)Elevation of C-reactive protein in “active” coronary artery disease Am J Cardiol. 65 168-172
[9]  
Blair SN(2003)High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study Circulation. 108 1560-1566
[10]  
Bonow RO(1994)The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina N Engl J Med. 331 417-424